ClinicalTrials.gg

Program

ivonescimab

Also written as “AK112”, “Ivonescimab” and “Ivonescimab Injection”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Ovarian Neoplasms · Triple Negative Breast Neoplasms · Small Cell Lung Carcinoma, led by 5 companies.

Furthest: phase 3, since Dec 21, 202148 company-led studies, 39 open or runningLicense: Akeso → Summit Therapeutics, Dec 2022Next primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akeso3930 open or runningphase 3since Dec 21, 2021Aug 5, 2019Dec 2026phase 2 · NCT05689853
Summit Therapeutics66 open or runningphase 3since Jun 1, 2023Jun 1, 2023Apr 2028phase 3 · NCT06767514
GlaxoSmithKline11 open or runningphase 2since May 15, 2026May 15, 2026Jun 22, 2029phase 2 · NCT07602855
Multitude Therapeutics11 open or runningphase 2since May 10, 2026May 10, 2026May 30, 2027phase 2 · NCT07590531
Shanghai Allink Biotherapeutics11 open or runningphase 2since Jul 29, 2026Jul 29, 2026Dec 31, 2027phase 2 · NCT07742956

Also a collaborator on its studies: shanghai-virogin-biotech-co-ltd.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How GlaxoSmithKline, Multitude Therapeutics and Shanghai Allink Biotherapeutics relate to it is not in the registry or these sources.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 31 studies since Aug 5, 2019.

  1. Mar 10, 2025Phase 2 study in Biliary Tract NeoplasmsAkeso · NCT06938321 · 135 planned · China
  2. Apr 8, 20253 phase 3 studiesAkeso · NCT06928389, NCT06951503, NCT06953999
  3. May 25, 2025Phase 3 study in Small Cell Lung CarcinomaAkeso · NCT07010263 · 560 planned · China
  4. Aug 3, 20252 phase 2 studiesAkeso · NCT07114315, NCT07158840
  5. Sep 29, 2025Phase 2 study in Small Cell Lung CarcinomaAkeso · NCT07245446 · 180 planned · China
  6. Nov 10, 2025Phase 3 study in Colorectal NeoplasmsSummit Therapeutics · NCT07228832 · 900 planned · United States, Belgium, Canada and more
  7. Dec 24, 2025Phase 2 study in Colorectal Cancer With Hepatic MetastasesAkeso · NCT07357220 · 72 planned · China
  8. Jan 6, 2026Phase 1 study in Healthy Male SubjectsAkeso · NCT07340476 · 108 enrolled · China
  9. May 10, 2026Multitude Therapeutics's first study: phase 2 study in Advanced Non-small Cell Lung Cancer (NSCLC)New to Multitude TherapeuticsMultitude Therapeutics · NCT07590531 · 118 planned · China
  10. May 15, 2026GlaxoSmithKline's first study: phase 2 study in Lung NeoplasmsNew to GlaxoSmithKlineGlaxoSmithKline · NCT07602855 · 184 planned · United States, Japan
  11. Jun 21, 2026Phase 2 study in Advanced Non Small Cell Lung Cancer (NSCLC)Akeso · NCT07669779 · 348 planned · China
  12. Jul 29, 2026Shanghai Allink Biotherapeutics's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Shanghai Allink BiotherapeuticsShanghai Allink Biotherapeutics · NCT07742956 · 156 planned
  13. Aug 31, 2026Phase 3 study in Carcinoma, Transitional CellSummit Therapeutics · NCT07815665 · 800 planned · United States
  14. Sep 29, 2026Phase 2 study in Carcinoma, Renal CellSummit Therapeutics · NCT07877194 · 100 planned · United States, China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Triple Negative Breast NeoplasmsAkeso · NCT06767527
  2. Dec 2026Primary completion: phase 2 study in Solid Tumor, AdultAkeso · NCT05689853
  3. Dec 30, 2026Primary completion: phase 2 study in Metastatic Pancreatic Ductal AdenocarcinomaAkeso · NCT06646055
  4. Dec 30, 2026Primary completion: phase 2 study in Triple Negative Breast NeoplasmsAkeso · NCT05227664

TargetBeta

PDCD1 →VEGFA →read by rule
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
tivunatamigPfizerphase 315
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
ABBV-1480RemeGenphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010Merckphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039AruleMinghui Pharmaceuticalphase 23
Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rulewigen-biomedicine-technology-shanghai-co-ltdphase 22
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rulecompass-therapeuticsphase 11

Studies

All 48 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07877194Carcinoma, Renal Cell · United States, China2Not yet recruitingSummit TherapeuticsApr 12, 2029100
NCT07815665Carcinoma, Transitional Cell · United States3RecruitingSummit TherapeuticsOct 31, 2030800
NCT07742956Carcinoma, Non-Small-Cell Lung2Not yet recruitingShanghai Allink BiotherapeuticsDec 31, 2027156
NCT07669779Advanced Non Small Cell Lung Cancer (NSCLC) · China2RecruitingAkesoAug 30, 2027348
NCT07602855Lung Neoplasms · United States, Japan2RecruitingGlaxoSmithKlineJun 22, 2029184
NCT07590531Advanced Non-small Cell Lung Cancer (NSCLC) · China2RecruitingMultitude TherapeuticsMay 30, 2027118
NCT07340476Healthy Male Subjects · China1Active, not recruitingAkesoApr 10, 2026108
NCT07357220Colorectal Cancer With Hepatic Metastases · China2Not yet recruitingAkesoFeb 28, 202772
NCT07228832Colorectal Neoplasms · United States, Belgium, Canada and more3RecruitingSummit TherapeuticsMay 31, 2028900
NCT07245446Small Cell Lung Carcinoma · China2RecruitingAkesoDec 2027180
NCT07158840Carcinoma, Non-Small-Cell Lung · China2Not yet recruitingAkesoSep 202860
NCT07114315Pancreatic Neoplasms · China2RecruitingAkesoAug 2027160
NCT07010263Small Cell Lung Carcinoma · China3RecruitingAkesoDec 31, 2028560
NCT06953999Pancreatic Neoplasms · China3RecruitingAkesoMay 14, 2027999
NCT06951503Colorectal Adenocarcinoma · China3RecruitingAkesoJan 13, 2027560
NCT06928389Carcinoma, Non-Small-Cell Lung · China3RecruitingAkesoMay 2027536
NCT06938321Biliary Tract Neoplasms · China2RecruitingAkesoMay 2027135
NCT06767527Triple Negative Breast Neoplasms · China3RecruitingAkesoDec 2026416
NCT06767514Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more3RecruitingSummit TherapeuticsApr 2028780
NCT06686030Platinum-sensitive Ovarian Cancer · China2RecruitingAkesoOct 2027150
NCT06646055Metastatic Pancreatic Ductal Adenocarcinoma · China2Active, not recruitingAkesoDec 30, 2026110
NCT06591520Biliary Tract Neoplasms · China3Active, not recruitingAkesoOct 2026682
NCT06601335Squamous Cell Carcinoma of Head and Neck · China3RecruitingAkesoJan 2027510
NCT06560112Ovarian Neoplasms · China2RecruitingAkesoMay 1, 2026172
NCT06530251Carcinoma, Hepatocellular · China2RecruitingAkesoJun 2026280
NCT06396065Non-Squamous Non-small Cell Lung Cancer · United States, Canada, France and more3Active, not recruitingSummit TherapeuticsApr 12, 2025420
NCT05951608Advanced Solid Tumors · China2Active, not recruitingAkesoMay 1, 2026216
NCT05899608Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more3Active, not recruitingSummit TherapeuticsDec 31, 20281,600
NCT05904379Advanced Non-small-cell Lung Cancer · China2Active, not recruitingAkesoJun 30, 2026233
NCT05846867Colorectal Neoplasms · China2Active, not recruitingAkesoMay 8, 2026170
NCT05840016Advanced Squamous Non Small Cell Lung Cancer · China3Active, not recruitingAkesoFeb 28, 2025532
NCT05689853Solid Tumor, Adult · China2RecruitingAkesoDec 202687
NCT05636267NSCLC · China2TerminatedAkesoFeb 24, 202559
NCT05499390Advanced Non-small-cell Lung Cancer · China3Active, not recruitingAkesoJan 29, 2024398
NCT05432492Carcinoma, Hepatocellular · China2CompletedAkesoApr 30, 202540
NCT05382442Colorectal Neoplasms · United States, China2Active, not recruitingAkesoMay 15, 2026254
NCT05229497Advanced Malignant Tumors · China2Active, not recruitingAkesoDec 31, 2026154
NCT05227664Triple Negative Breast Neoplasms · China2Active, not recruitingAkesoDec 30, 2026120
NCT05247684Resectable Non-small Cell Lung Cancer · China2Active, not recruitingAkesoAug 18, 202590
NCT05214482Advanced Malignant Tumors · China2CompletedAkesoNov 20, 2025154
NCT05184712Non-Squamous Non-small Cell Lung Cancer · China3Active, not recruitingAkesoMar 10, 2023322
NCT05116007SCLC, Extensive Stage · China1CompletedAkesoDec 4, 202335
NCT04999605Ovarian Neoplasms · China2TerminatedAkesoJun 10, 20228
NCT04900363Carcinoma, Non-Small-Cell Lung · China2CompletedAkesoJun 28, 2024108
NCT04870177Neoplasm Metastasis · China2CompletedAkesoMay 10, 202453
NCT04736823NSCLC · China2Active, not recruitingAkesoJul 2026265
NCT04597541Solid Tumor, Adult · China2CompletedAkesoMar 31, 202259
NCT04047290Neoplasms · Australia1CompletedAkesoFeb 27, 202480

How it is read

Names in the registry

  • “AK112”, 27 entries
  • “Ivonescimab”, 3 entries
  • “Ivonescimab Injection”, 3 entries
  • “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
  • “AK112 Injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.